DMPs (disease management programmes) must address the innovation issue, says firm
This article was originally published in Clinica
The German government's disease management programmes (DMPs) should be used as an opportunity to introduce innovative medical technology for the treatment of the chronically ill, says the medical device industry association (BVMed). In a letter to the co-ordination committee, which is to oversee the detailed structure of the DMPs, BVMed reiterated its call for industry and business expertise to be given a role in their construction.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.